Literature DB >> 21700258

Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy.

Jeffrey B Geske1, Paul Sorajja, Steve R Ommen, Rick A Nishimura.   

Abstract

OBJECTIVES: This study characterizes left ventricular outflow tract (LVOT) gradient variability in patients with hypertrophic cardiomyopathy (HCM) during cardiac catheterization.
BACKGROUND: Management of HCM is directed by the presence and magnitude of LVOT obstruction. The magnitude and clinical impact of spontaneous variability during a single cardiac catheterization has not been described.
METHODS: Fifty symptomatic patients with HCM (mean age 55 ± 15 years; 48% men) underwent cardiac catheterization with high-fidelity, micromanometer-tip catheters and transseptal measurement of left ventricular pressures. Obstruction was defined as resting LVOT gradient ≥ 30 mm Hg and severe obstruction as ≥ 50 mm Hg. Variability in LVOT gradient was calculated as the difference of the largest and smallest LVOT gradients in the absence of provocative maneuvers or interventions.
RESULTS: The largest LVOT gradient was 54.6 ± 56.4 mm Hg. The spontaneous variability in LVOT gradient was 49.0 ± 53.1 mm Hg (range 0 to 210.8 mm Hg, median 15 mm Hg). Discrepant classification of resting LVOT gradient severity was possible in 25 patients (50%). Twenty patients (40%) with severe obstruction could have been misclassified with regard to obstruction severity.
CONCLUSIONS: In patients with HCM, the LVOT gradient fluctuates significantly during a single hemodynamic assessment. Spontaneous variability could lead to misclassification of obstruction severity in one-half of studied patients. The dynamic nature of LVOT obstruction must be considered when assessing resting hemodynamics or the success of a given intervention during cardiac catheterization.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700258     DOI: 10.1016/j.jcin.2011.02.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

1.  Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance.

Authors:  Bradley D Allen; Lubna Choudhury; Alex J Barker; Pim van Ooij; Jeremy D Collins; Robert O Bonow; James C Carr; Michael Markl
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-08-09       Impact factor: 6.875

Review 2.  Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.

Authors:  Daniel J Philipson; Eugene C DePasquale; Eric H Yang; Arnold S Baas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

3.  Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.

Authors:  Sammy Elmariah; Michael A Fifer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

Review 4.  Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Authors:  C Charles Jain; Darrell B Newman; Jeffrey B Geske
Journal:  Curr Cardiol Rep       Date:  2019-10-31       Impact factor: 2.931

Review 5.  Clinical Characteristics and Treatment of Cardiomyopathies in Children.

Authors:  Jack F Price; Aamir Jeewa; Susan W Denfield
Journal:  Curr Cardiol Rev       Date:  2016

6.  Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods.

Authors:  Mateusz Śpiewak; Mariusz Kłopotowski; Monika Gawor; Agata Kubik; Ewa Kowalik; Barbara Miłosz-Wieczorek; Maciej Dąbrowski; Konrad Werys; Łukasz Mazurkiewicz; Katarzyna Kożuch; Magdalena Polańska-Skrzypczyk; Joanna Petryka-Mazurkiewicz; Anna Klisiewicz; Zofia T Bilińska; Jacek Grzybowski; Adam Witkowski; Magdalena Marczak
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-21       Impact factor: 5.364

7.  Gradient variability in hypertrophic cardiomyopathy: New insights from computer-assisted, high fidelity, rest and exercise hemodynamic analysis.

Authors:  Terry D Bauch; Alexandra J Smith; Joseph P Murgo; James A Watts; Bernard J Rubal
Journal:  Catheter Cardiovasc Interv       Date:  2018-11-25       Impact factor: 2.692

8.  The novel mitochondrial 16S rRNA 2336T>C mutation is associated with hypertrophic cardiomyopathy.

Authors:  Zhong Liu; Yanrui Song; Dan Li; Xiangyu He; Shishi Li; Bifeng Wu; Wei Wang; Shulian Gu; Xiaoyu Zhu; Xuexiang Wang; Qiyin Zhou; Yu Dai; Qingfeng Yan
Journal:  J Med Genet       Date:  2013-12-23       Impact factor: 6.318

9.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.

Authors:  Konstantinos C Siontis; Jeffrey B Geske; Kevin Ong; Rick A Nishimura; Steve R Ommen; Bernard J Gersh
Journal:  J Am Heart Assoc       Date:  2014-06-25       Impact factor: 5.501

10.  A Multiphysics Biventricular Cardiac Model: Simulations With a Left-Ventricular Assist Device.

Authors:  Azam Ahmad Bakir; Amr Al Abed; Michael C Stevens; Nigel H Lovell; Socrates Dokos
Journal:  Front Physiol       Date:  2018-09-11       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.